Have a personal or library account? Click to login
Immune-Mediated Adverse Effects of Checkpoint Inhibitors: A Clinical Experience Cover

Immune-Mediated Adverse Effects of Checkpoint Inhibitors: A Clinical Experience

European Pharmaceutical Journal
Volume 69 (2022): Issue s1 (July 2022)
By: Jan Juřica,  Roman Goněc,  Adela Bártová and  Jana Gregorová  
Open Access
|Jun 2022

References

  1. Khan S, Gerber DE. Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: A review. Semin Cancer Biol. 2020;64,93–101.
    Search in Google ScholarBack to article
  2. Wang PF, Chen Y, Song SY et al. Immune-related adverse events associated with anti-PD-1/PD-L1 treatment for malignancies: A meta-analysis. Front Pharmacol. 2017;8,730.
    Search in Google ScholarBack to article
DOI: https://doi.org/10.2478/afpuc-2022-0006 | Journal eISSN: 2453-6725
Journal RSS Feed
Language: English
Page range: 84 - 86
Submitted on: Apr 25, 2022
Accepted on: May 10, 2022
Published on: Jun 18, 2022
Published by: Comenius University in Bratislava, Faculty of Pharmacy
In partnership with: Paradigm Publishing Services
Publication frequency: 2 issues per year
Keywords:
Immune checkpoint inhibitors,
immunotherapy,
adverse effect,
autoimmunity
Related subjects:
Pharmacy,
Pharmacy, other

© 2022 Jan Juřica, Roman Goněc, Adela Bártová, Jana Gregorová, published by Comenius University in Bratislava, Faculty of Pharmacy
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Previous articleVolume 69 (2022): Issue s1 (July 2022)Next article